Navigation Links
Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
Date:2/25/2009

s evaluated using RECIST (Response Evaluation Criteria in Solid Tumors; an internationally recognized measure of disease progression) in patients with measureable disease showed an overall response rate of 8 percent (one partial response in 13 patients with measureable disease) and a 54 percent disease control rate (six of 13 patients with measureable disease). In comparison, published literature reports overall response rates of 8 to 12 percent in patients treated with docetaxel alone.
  • These data indicate that picoplatin can be safely administered with full-dose docetaxel. Neutropenia was the main hematologic toxicity. Thrombocytopenia was less severe and less frequent with picoplatin administered in combination with docetaxel compared with picoplatin administered alone.
  • These findings confirm and extend earlier Phase 2 results presented at the 20th European Organization for Research and Treatment of Cancer - National Cancer Institute - American Association for Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer" in Geneva, Switzerland, in October 2008.

    "The encouraging PSA response rates, time to PSA progression and radiologic responses rates, combined with the promising safety results observed to date, support further development of picoplatin in combination with docetaxel and prednisone in advanced prostate cancer patients," said Robert De Jager, M.D., chief medical officer of Poniard. "We continue to collect and analyze data from this trial and expect to present updated clinical data, including time to disease progression and overall survival, at medical conferences later this year."

    About Picoplatin

    Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Study data to date indicate that it has an improved safety profile relative to existing platinum-based cancer therapies
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
    2. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
    3. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
    4. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
    5. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
    6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
    7. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
    8. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
    9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
    10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
    11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
    (Date:9/18/2014)... 18, 2014 HealthTronics, Inc ... interventional radiology products and services, announced that a ... and cryoablation) versus external beam radiotherapy (EBRT) is ... American Urological Association (MAAUA) Annual Meeting in Baltimore, ... Effectiveness of Cryosurgery and External Beam Radiation as ...
    (Date:9/18/2014)... September 18, 2014 A novel robotic ... MRI scanner is currently being tested as part of ... Hospital in Boston with the aim of determining if ... make prostate cancer biopsies faster, more accurate, less costly, ... also has the potential to deliver prostate cancer therapies ...
    (Date:9/18/2014)... 2014 Texas Governor Rick Perry, ... A&M Health Science Center CEO Brett Giroir, M.D., ... and Human Services (HHS), State of Texas and ... influenza vaccine manufacturing facility in Bryan, Texas, which ... the Texas A&M Biocorridor – a rapidly evolving ...
    Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
    ... Reportlinker.com announces that a new market research ... Propylene Oxide: 2010 World Market Outlook And ... The report analyzes worldwide markets for Propylene ... America. It provides the most complete and current ...
    ... Feb. 24, 2011 Palatin Technologies, Inc. (NYSE Amex: ... public offering of 23,000,000 units, consisting of 23,000,000 shares of ... of its common stock and Series B Warrants to purchase ... the public of $1.00 per unit. Palatin expects that the ...
    ... Quest Diagnostics Incorporated (NYSE: DGX ), ... services, announced today that it has signed a definitive ... in genetic testing for neurological disorders, from Thermo Fisher ... in cash.   Athena Diagnostics is the ...
    Cached Biology Technology:Reportlinker Adds Propylene Oxide: 2010 World Market Outlook and Forecast 2Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 2Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants 3Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market 2Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market 3Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market 4
    (Date:9/18/2014)... many times it,s demonstrated, it,s still hard to ... But by using a signaling system called "quorum ... to suit their population. In short, some bacteria ... act accordingly. , Once the population of quorum-sensing ... innocuous to pathogenic, or from unhelpful to helpful. ...
    (Date:9/18/2014)... Sept. 18, 2014 -- Arizona turned its newborn screening ... a few short months, earning it the first-ever Newborn Screening ... March of Dimes presented Will Humble, M.P.H., Arizona,s Department of ... here today. Mr. Humble established a policy of full transparency ... send newborn blood samples to the lab for analysis, and ...
    (Date:9/18/2014)... comprise all spheres of our planet. Manifold interactions ... and perturbations that resulted in increases of the ... climate changes which influence the complex biogeochemical processes ... these feedback mechanisms has become an important new ... past three decades. , In parallel, a novel ...
    Breaking Biology News(10 mins):Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Greenhouse gas research enters a new era 2
    ... and the University of Sheffield have applied computing power to crack ... a partial answer to the age old question "what came first ... in this context is "chicken" or at least a particular ... particular chicken protein turns out to come both first and last. ...
    ... 2010) -- The Damon Runyon Cancer Research Foundation, ... career researchers and innovative cancer research, named 18 ... Award Committee review. The recipients of this ... basic and translational cancer research in the laboratories ...
    ... A North Carolina State University entomologist has for the ... termite queens to prevent other termites in the colony from ... In a study published online this week in ... Dr. Ed Vargo and colleagues from Japan and Switzerland show ...
    Cached Biology News:Researchers apply computing power to crack egg shell problem 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 4Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 5Damon Runyon Cancer Research Foundation awards prestigious fellowships to 18 top young scientists 6Don't let your termites grow up to be mommies 2
    Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
    ...
    Mouse monoclonal antibody raised against a partial recombinant ZNF155. NCBI Entrez Gene ID = ZNF155...
    ... is a sample preparation kit for reduction ... of detergents, phenolic compounds, salts, and most ... samples. The kit procedure involves a TCA-like ... or cells, plant leaves, E. coli, and ...
    Biology Products: